Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.

Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M.

Haematologica. 2019 Oct 17. pii: haematol.2019.224956. doi: 10.3324/haematol.2019.224956. [Epub ahead of print]

2.

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.

Abdel-Aziz AK, Saadeldin MK, D'Amico P, Orecchioni S, Bertolini F, Curigliano G, Minucci S.

Eur J Cancer. 2019 Nov;122:22-41. doi: 10.1016/j.ejca.2019.08.013. Epub 2019 Oct 10. Review.

PMID:
31606656
3.

Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.

Tabanelli V, Corsini C, Fiori S, Agostinelli C, Calleri A, Orecchioni S, Melle F, Motta G, Rotili A, Di Napoli A, Pileri SA.

Hum Pathol. 2019 Aug;90:60-69. doi: 10.1016/j.humpath.2019.05.007. Epub 2019 May 21.

PMID:
31125630
4.

Identifying Drug Repurposing Opportunities in Oncology.

Orecchioni S, Roma S, Raimondi S, Gandini S, Bertolini F.

Cancer J. 2019 Mar/Apr;25(2):82-87. doi: 10.1097/PPO.0000000000000360.

PMID:
30896529
5.

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.

Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A, Motta G, Rossi M, Agostinelli C, Sabattini E, Pimpinelli N, Truni M, Falini B, Cerroni L, Talarico G, Piccioni R, Amente S, Indio V, Tarantino G, Brundu F, Paulli M, Berti E, Facchetti F, Dellino GI, Bertolini F, Tripodo C, Rabadan R, Pileri SA.

Haematologica. 2019 Apr;104(4):729-737. doi: 10.3324/haematol.2018.202093. Epub 2018 Oct 31.

6.

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.

Sanchez-Martinez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo DN, Rene C, Lu ZY, Krzywinska E, Anel A, Galvez EM, Pardo J, Robert B, Martineau P, Hicheri Y, Bertolini F, Cartron G, Villalba M.

Theranostics. 2018 Jun 14;8(14):3856-3869. doi: 10.7150/thno.25149. eCollection 2018.

7.

Mitochondrial Complex I activity signals antioxidant response through ERK5.

Khan AUH, Allende-Vega N, Gitenay D, Garaude J, Vo DN, Belkhala S, Gerbal-Chaloin S, Gondeau C, Daujat-Chavanieu M, Delettre C, Orecchioni S, Talarico G, Bertolini F, Anel A, Cuezva JM, Enriquez JA, Cartron G, Lecellier CH, Hernandez J, Villalba M.

Sci Rep. 2018 May 9;8(1):7420. doi: 10.1038/s41598-018-23884-4.

8.

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.

Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F.

Br J Cancer. 2018 May;118(10):1329-1336. doi: 10.1038/s41416-018-0076-z. Epub 2018 Apr 26.

9.

Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status.

Belkahla S, Haq Khan AU, Gitenay D, Alexia C, Gondeau C, Vo DN, Orecchioni S, Talarico G, Bertolini F, Cartron G, Hernandez J, Daujat-Chavanieu M, Allende-Vega N, Gonzalez MV.

Oncotarget. 2017 Dec 14;9(1):1114-1129. doi: 10.18632/oncotarget.23305. eCollection 2018 Jan 2.

10.

Stromal Cell-Derived Factor-1α Promotes Endothelial Colony-Forming Cell Migration Through the Ca2+-Dependent Activation of the Extracellular Signal-Regulated Kinase 1/2 and Phosphoinositide 3-Kinase/AKT Pathways.

Zuccolo E, Di Buduo C, Lodola F, Orecchioni S, Scarpellino G, Kheder DA, Poletto V, Guerra G, Bertolini F, Balduini A, Rosti V, Moccia F.

Stem Cells Dev. 2018 Jan 1;27(1):23-34. doi: 10.1089/scd.2017.0114. Epub 2017 Dec 11.

PMID:
29121817
11.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

12.

The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway.

Khan AUH, Allende-Vega N, Gitenay D, Gerbal-Chaloin S, Gondeau C, Vo DN, Belkahla S, Orecchioni S, Talarico G, Bertolini F, Bozic M, Valdivielso JM, Bejjani F, Jariel I, Lopez-Mejia IC, Fajas L, Lecellier CH, Hernandez J, Daujat M, Villalba M.

Sci Rep. 2017 Sep 6;7(1):10654. doi: 10.1038/s41598-017-10339-5.

13.

Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression.

Reggiani F, Labanca V, Mancuso P, Rabascio C, Talarico G, Orecchioni S, Manconi A, Bertolini F.

Cancer Res. 2017 Sep 15;77(18):5169-5182. doi: 10.1158/0008-5472.CAN-17-0914. Epub 2017 Jul 28.

14.

Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells.

Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di Virgilio F, Pezzi A, Cavo M, Lemoli RM, Curti A.

Oncotarget. 2017 Jan 24;8(4):5895-5908. doi: 10.18632/oncotarget.13927.

15.

Characterization of Cancer Stem Cells.

Orecchioni S, Bertolini F.

Methods Mol Biol. 2016;1464:49-62. Review.

PMID:
27858355
16.

Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production.

Khan AUH, Rathore MG, Allende-Vega N, Vo DN, Belkhala S, Orecchioni S, Talarico G, Bertolini F, Cartron G, Lecellier CH, Villalba M.

EBioMedicine. 2015 Nov 26;3:43-53. doi: 10.1016/j.ebiom.2015.11.045. eCollection 2016 Jan.

17.

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2016 Feb 5;6:20743. doi: 10.1038/srep20743. No abstract available.

18.

Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.

Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F.

Sci Rep. 2016 Jan 5;6:18673. doi: 10.1038/srep18673.

19.

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2015 Dec 17;5:18137. doi: 10.1038/srep18137. Erratum in: Sci Rep. 2016;6:20743.

20.

Mechanisms of obesity in the development of breast cancer.

Orecchioni S, Reggiani F, Talarico G, Bertolini F.

Discov Med. 2015 Sep;20(109):121-8. Review.

21.

Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) Cells.

Belloni E, Martin Padura I, Gerbino E, Orecchioni S, Fusar Imperatore F, Marighetti P, Bertalot G, Giuseppe Pelicci P, Bertolini F.

Sci Rep. 2015 Aug 12;5:13047. doi: 10.1038/srep13047.

22.

The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism.

Allende-Vega N, Krzywinska E, Orecchioni S, Lopez-Royuela N, Reggiani F, Talarico G, Rossi JF, Rossignol R, Hicheri Y, Cartron G, Bertolini F, Villalba M.

Oncotarget. 2015 Aug 7;6(22):19228-45.

23.

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.

Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, Meyer LH, Debatin KM, Orecchioni S, Bertolini F, Pelicci PG.

Mol Cancer Ther. 2015 Apr;14(4):889-98. doi: 10.1158/1535-7163.MCT-14-0276. Epub 2015 Feb 9.

24.

Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer.

Bertolini F, Orecchioni S, Petit JY, Kolonin MG.

Curr Opin Oncol. 2014 Nov;26(6):545-50. doi: 10.1097/CCO.0000000000000130. Review.

PMID:
25279961
25.

The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.

Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, Labanca V, Noonan DM, Dallaglio K, Albini A, Bertolini F.

Int J Cancer. 2015 Mar 15;136(6):E534-44. doi: 10.1002/ijc.29193. Epub 2014 Sep 18.

26.

Paradoxic effects of metformin on endothelial cells and angiogenesis.

Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F, Pfeffer U, Noonan DM, Albini A.

Carcinogenesis. 2014 May;35(5):1055-66. doi: 10.1093/carcin/bgu001. Epub 2014 Jan 13.

27.

Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.

Orecchioni S, Gregato G, Martin-Padura I, Reggiani F, Braidotti P, Mancuso P, Calleri A, Quarna J, Marighetti P, Aldeni C, Pruneri G, Martella S, Manconi A, Petit JY, Rietjens M, Bertolini F.

Cancer Res. 2013 Oct 1;73(19):5880-91. doi: 10.1158/0008-5472.CAN-13-0821. Epub 2013 Aug 5.

28.

Resonance frequency analysis assessment of implants placed with a simultaneous or a delayed approach in grafted and nongrafted sinus sites: a 12-month clinical study.

Di Lallo S, Ricci L, Orecchioni S, Piattelli A, Iezzi G, Perrotti V.

Clin Implant Dent Relat Res. 2014 Jun;16(3):394-400. doi: 10.1111/cid.12002. Epub 2012 Sep 11.

PMID:
22967171

Supplemental Content

Loading ...
Support Center